DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for amelogenesis imperfecta, IIa 1K — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAmelogenesis imperfecta, IIa 1K maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for amelogenesis imperfecta, iia 1k is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
The three items provided are all supplemental materials for a single 2023 study on amelogenesis imperfecta and ameloblastin variants. No abstract text is included, only file descriptions. The study itself is not accessible from these entries. No drug, no treatment, no patient outcome data, no survival or response rates are reported in the supplied text. The supplemental materials are labelled as a docx file and a pptx file, suggesting they contain additional figures or tables, but their content is not described.
Because the abstracts themselves are absent, there is no evidence to summarise. The only information is that the study concerns novel ameloblastin variants and contrasting phenotypes in amelogenesis imperfecta, and that it was published in the Journal of Dental Research in 2023. No conclusions about efficacy, safety, or any intervention can be drawn.
What is missing is the primary research article itself, any clinical trial data, any patient numbers, and any mention of a drug or repurposing strategy. Without the full abstract or the study text, no meaningful evidence summary is possible.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Sage Journals Data · 2023 · 0 citations · open access
sj-docx-1-jdr-10.1177_00220345231203694 – Supplemental material for Novel Ameloblastin Variants, Contrasting Amelogenesis Imperfecta Phenotypes
AbstractSupplemental material, sj-docx-1-jdr-10.1177_00220345231203694 for Novel Ameloblastin Variants, Contrasting Amelogenesis Imperfecta Phenotypes by U. Hany, C.M. Watson, L. Liu, G. Nikolopoulos, C.E.L. Smith, J.A. Poulter, C.J. Brown, A. Patel, H.D. Rodd, R. Balmer, A. Harfoush, M. Al-Jawad, C.F. Inglehearn and A.J. Mighell in Journal of Dental Research
INDIGO (University of Illinois at Chicago) · 2023 · 0 citations · open access
sj-docx-1-jdr-10.1177_00220345231203694 – Supplemental material for Novel Ameloblastin Variants, Contrasting Amelogenesis Imperfecta Phenotypes
AbstractSupplemental material, sj-docx-1-jdr-10.1177_00220345231203694 for Novel Ameloblastin Variants, Contrasting Amelogenesis Imperfecta Phenotypes by U. Hany, C.M. Watson, L. Liu, G. Nikolopoulos, C.E.L. Smith, J.A. Poulter, C.J. Brown, A. Patel, H.D. Rodd, R. Balmer, A. Harfoush, M. Al-Jawad, C.F. Inglehearn and A.J. Mighell in Journal of Dental Research
Sage Journals Data · 2023 · 0 citations · open access
sj-pptx-1-jdr-10.1177_00220345231203694 – Supplemental material for Novel Ameloblastin Variants, Contrasting Amelogenesis Imperfecta Phenotypes
AbstractSupplemental material, sj-pptx-1-jdr-10.1177_00220345231203694 for Novel Ameloblastin Variants, Contrasting Amelogenesis Imperfecta Phenotypes by U. Hany, C.M. Watson, L. Liu, G. Nikolopoulos, C.E.L. Smith, J.A. Poulter, C.J. Brown, A. Patel, H.D. Rodd, R. Balmer, A. Harfoush, M. Al-Jawad, C.F. Inglehearn and A.J. Mighell in Journal of Dental Research
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
